Business Wire

GALDERMA

Share
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport ® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus placebo for the treatment of moderate to severe frown lines between the eyebrows (glabellar lines). Results showed that the study met its primary endpoint, with significantly more subjects treated with Dysport ® at all four doses achieving a composite two grade improvement responder rate than those treated with placebo at one month. Data from secondary endpoints demonstrated promising results for a potential prolonged duration of effect correlated with higher doses. Dysport ® , also marketed as Azzalure® in some countries, is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines in adults less than 65 years of age.

“We are encouraged that these study results demonstrate that a single dose of Dysport ® has a rapid onset, long-lasting effect and is well tolerated,” said John H. Joseph, M.D., investigator for the study and director of The Clinical Testing Center of Beverly Hills. “At all doses tested in the trial, Dysport ® had a strong safety profile, including very few cases of eyelid ptosis.”

Phase 2 Dose-Escalating Study Design and Results
The multicenter, randomized, dose-ranging, double-blind, placebo-controlled Phase 2 study enrolled 401 subjects ages 18 to 65 with moderate to severe glabellar lines at maximum frown. Study participants were randomized 4:1 to receive a single dose of Dysport ® (50U, the dose in the FDA-approved label, 75U, 100U or 125U) or placebo and followed for nine months. The primary objective of the study was to evaluate the efficacy of a single dose of Dysport ® as assessed by the composite responder rate at maximum frown at one month. Secondary objectives evaluated other measures of efficacy as well as duration of treatment response, subject satisfaction, aesthetic improvement and onset of treatment response.

Top-line efficacy results showed that the study met its primary endpoint. After one month, all dose groups treated with Dysport ® showed a statistically significant composite (investigator and subject-assessed) ≥2-grade improvement when compared with placebo. Favorable results were achieved for all doses in the secondary objectives, including a ≥1-grade improvement and subject satisfaction throughout the study duration. Dysport ® was well tolerated with a similar safety profile across all doses tested. Treatment-related adverse events were mild or moderate in severity and transient, and no treatment-related serious adverse events were reported.

“This phase 2 study underscores our commitment to bring efficacious products and long-lasting results to customers,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Based on these encouraging safety and long-term efficacy results, as well as continued patient satisfaction, we are evaluating future clinical studies.”

About Galderma's collaboration with Ipsen
Dysport ® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport is also marketed as Azzalure® in the EU for the treatment of glabellar lines with more than 40 million treatments in the EU and U.S. combined and with approvals in 74 countries.

Dysport ® is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen's botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, the European Union, Australia, South Korea, Canada, Brazil, Argentina, and certain other countries. Ipsen continues to promote Dysport ® within certain therapeutic indications in countries around the world.
For more information on Ipsen, visit www.ipsen.com .

About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com/ .

# # #

Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088.

For U.S. audiences please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com .

The Dysport trademark is used under license. All trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fanatics Collectibles and Kayou Join Forces to Bring NBA Trading Cards to China3.10.2025 04:00:00 CEST | Press release

NBA Match Attax 2025 to launch on Oct. 3 at retail locations across ChinaFanatics Collectibles kicks off licensed basketball with presence at NBA China Games Fanatics Collectibles, via Topps, and Kayou have announced today a partnership to provide NBA trading cards to China through NBA Match Attax 2025. The deal represents a landmark product offering accessible NBA trading cards for basketball fans in China and further growing the country’s passion for the sport. As part of the deal, Kayou, a leading trading card manufacturer in China, will handle the manufacturing and distribution of the product, leveraging its expansive existing distribution network, while Topps will utilize its world class design to delight Chinese fans and collectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002665209/en/ The deal underscores Fanatics Collectibles’ commitment to growing the Chinese market, as well as its international growth str

With the Redevelopment Works Underway, UCC Holding on behalf of the JV Partners Signs Five Design and Consultancy Agreements with Global Firms for the Development of Damascus International Airport2.10.2025 20:37:00 CEST | Press release

UCC Holding, on behalf of the JV partners and through its subsidiary Urbacon Airports, has signed five consultancy and design agreements as part of the Damascus International Airport comprehensive redevelopment project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002746016/en/ UCC Holding on behalf of the JV Partners Signs Five Design and Consultancy Agreements with Global Firms for the Development of Damascus International Airport (Photo: AETOSWire) Scopes include the redevelopment of the airport and all associated facilities — a phased redevelopment designed to reach 31 million passengers annually. This includes the refurbishment of existing terminals and buildings, as well as the design and development of a new five-star hotel adjacent to the airport, featuring 200 premium rooms, multiple dining and leisure facilities, and direct terminal access. The hotel will be managed and operated by an internationally recognize

Stefanini Group Ranked Exceptional Performer for Customer Satisfaction by Whitelane 2025 Swiss IT Sourcing Study2.10.2025 19:52:00 CEST | Press release

The tech company achieved the highest general satisfaction ranking with scores of 85% in the Whitelane Research study. Stefanini Group, a global technology company specializing in digital transformation and AI solutions, announced today that it was awarded the title “Exceptional Performer” for General Customer Satisfaction and Workplace Services in the Whitelane 2025 Swiss IT Sourcing Study. Debuting in the research this year, Stefanini achieved the highest general satisfaction ranking with scores of 85%, compared to the industry average of 78 percent. The company was also ranked number one for Workplace Services (83% vs. 79% industry average), considering several key performance indicators (KPIs). “All Stefanini KPI scores are great, but Account Management is truly outstanding (94% compared with 79% industry average). This KPI evaluates how Stefanini manages their relationship with clients, from a strategic and commercial perspective, and identifies new areas for cooperation and impro

Andersen Consulting udvider sine kapaciteter i Mauritius og Seychellerne2.10.2025 19:12:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kapaciteter med tilføjelsen af samarbejdspartneren Perigeum Capital Ltd, der er en førende rådgivningsvirksomhed inden for virksomhedsfinansiering med hovedkontor i Mauritius og kontor i Seychellerne. Perigeum Capital tilbyder en omfattende portefølje af professionelle tjenester, herunder rådgivning inden for virksomhedsfinansiering, kapitalmarkedsløsninger, fusion og opløb, værdiansættelse, it-konsulentydelser, compliance, ledelse og ESG-rådgivning. Med ekspertise inden for både lokale, regionale og internationale regulatoriske rammer samarbejder virksomheden med organisationer gennem hele deres vækst- og transformationsrejser. Virksomhedens kapaciteter suppleres af specialiseret viden inden for teknologi – herunder kunstig intelligens, cybersikkerhed samt data og analyse – hvilket øger dybden og resiliensen af deres rådgivning. Denne integrerede tilgang gør Perigeum Capital til en komplet og pålidelig ressource til helhedsorienterede rådgivnings- og t

Zayed Sustainability Prize Announces 2026 Finalists Driving Global Impact2.10.2025 17:51:00 CEST | Press release

33 finalists selected from 7,761 submissions across 173 countriesThis year’s finalists are pioneering inclusive, tech-enabled, and locally adapted solutions that tackle urgent global challenges—delivering clean energy, safe water, nutritious food, quality healthcare, and climate resilience to millions worldwideThe Prize’s global impact has reached over 400 million lives, demonstrating the power of innovation to transform communities and shape a sustainable future The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has announced this year’s finalists following a rigorous evaluation by its esteemed Jury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002639589/en/ The Zayed Sustainability Prize convened in Abu Dhabi to select the 33 finalists of the 2026 edition (Photo: AETOSWire) The winners will be revealed at the Zayed Sustainability Prize Awards Ceremony on 13 Januar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye